| Literature DB >> 34886097 |
Shirin Kahremany1,2, Lukas Hofmann1, Noy Eretz-Kdosha2, Eldad Silberstein3, Arie Gruzman1, Guy Cohen2,4.
Abstract
Air pollution has been repeatedly linked to numerous health-related disorders, including skin sensitization, oxidative imbalance, premature extrinsic aging, skin inflammation, and increased cancer prevalence. Nrf2 is a key player in the endogenous protective mechanism of the skin. We hypothesized that pharmacological activation of Nrf2 might reduce the deleterious action of diesel particulate matter (DPM), evaluated in HaCaT cells. SK-119, a recently synthesized pharmacological agent as well as 2,2'-((1E,1'E)-(1,4-phenylenebis(azaneylylidene))bis(methaneylylidene))bis(benzene-1,3,5-triol) (SH-29) were first evaluated in silico, suggesting a potent Nrf2 activation capacity that was validated in vitro. In addition, both compounds were able to attenuate key pathways underlying DPM damage, including cytosolic and mitochondrial reactive oxygen species (ROS) generation, tested by DC-FDA and MitoSOX fluorescent dye, respectively. This effect was independent of the low direct scavenging ability of the compounds. In addition, both SK-119 and SH-29 were able to reduce DPM-induced IL-8 hypersecretion in pharmacologically relevant concentrations. Lastly, the safety of both compounds was evaluated and demonstrated in the ex vivo human skin organ culture model. Collectively, these results suggest that Nrf2 activation by SK-119 and SH-29 can revert the deleterious action of air pollution.Entities:
Keywords: 2,2′-((1E,1′E)-(1,4-phenylenebis(azaneylylidene))bis(methaneylylidene))bis(benzene-1,3,5-triol (SH-29)); Nrf2; ROS; diesel particulate matter (DPM) (E)-5-oxo-1-(4-((2,4,6-trihydroxybenzylidene)amino)phenyl)pyrrolidine-3-carboxylic acid (SK-119); keratinocytes; pharmacological activators
Mesh:
Substances:
Year: 2021 PMID: 34886097 PMCID: PMC8656889 DOI: 10.3390/ijerph182312371
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Designed workflow for in silico simulations of SH-29 and SK-119.
Figure 2Docking pose of SH-29 (green) and SK-119 (orange) and their amino acid interactions with the binding site of Keap1. Ligands are represented in ball and stick.
Figure 3The total binding free energies of compound SH-29 (dark blue) and compound SK-119 (light blue) and the contribution of various interactions such as coulomb—coulomb energy, covalent—covalent binding energy, Hbond—H-bond energy, lipo—lipophilic energy, SolvGB—generalized born electrostatic solvation energy, vdw—Van der Waals energy.
Binding free energy results on SH-29 and SK-119.
| Compound | ∆Gbind a | ∆Gcoulomb b | ∆Gcovalent c | ∆GH-bond d | ∆Gsol lipo e | ∆Gsol GB f | ∆Gvdw g |
|---|---|---|---|---|---|---|---|
| SH-29 | −54.58 | 6.62 | 2.17 | −1.27 | −16.53 | −22.94 | −22.01 |
| SK-119 | −49.48 | 1.09 | 5.72 | −2.86 | −20.97 | −3.49 | −28.9 |
a Free binding energy. b Coulomb energy contribution to the binding free energy. c Covalent energy contribution to the binding free energy. d H-bond energy contribution to the binding free energy. e The surface area due to lipophilic energy contribution to the binding free energy. f The generalized born electrostatic solvation energy contribution to the binding free energy. g Van der Waal’s energy contribution to the binding free energy.
Figure 4Representation of HOMO, LUMO, and MESP on compound SH-29 and compound SK-119.
Single point energy value of frontier orbital energies and electrostatic potential.
| Compound | HOMO (ev) | LUMO (ev) | HOMO-LUMO GAP (ev) | MESP (kcal/mol) |
|---|---|---|---|---|
| SH-29 | −0.222 | −0.113 | 0.109 | −6.94 to 150.47 |
| SK-119 | −0.127 | −0.014 | 0.114 | −167.78 to 39.83 |
Figure 5SH-29 and SK-119 activate Nrf2 in vitro. HaCaT keratinocyte cells were treated w/o or with 50 or 100 µg/mL of SH-29 or SK-119. After 2 h, cell viability was determined by the MTT assay (A). Concomitantly, the nuclear fraction was isolated, and Nrf2 activation was determined as written in the material and method section above (B). n = 3; * p < 0.05 for signification different from naïve control cells. C—control; V—vehicle, DMSO at 0.1%; SH for SH-29 and SK for SK-119.
Figure 6SH-29 and SK-119 attenuate DPM-induced damage. HaCaT cells were treated w/o or with the indicated SH-29 or SK-119 concentration and exposed to DPM. After 45 min., cytosolic (A) or mitochondrial (B) ROS levels were measured by DC-FDA or MitoSOX, respectively. After 24 h, IL-8 secretion (C) and cell viability (D) were determined by designated ELISA assay and MTT. In addition, the direct ROS scavenging capacity was evaluated by the DPPH method (E). n = 3; */# p < 0.05 for signification different from naïve control cells or DPM-stimulated group, respectively. C—control; D—DPM; V—vehicle, DMSO at 0.1%; N—N-acetylcysteine; SH for SH-29 and SK for SK-119.
Figure 7Safety evaluation of SH-29 and SK-119 in the ex vivo human skin organ culture. The compounds were applied topically on the epidermal layer of the skin samples in the indicated concentrations. After 24 h, epidermal viability was determined by the MTT assay (A). Concomitantly, IL-1α levels in the spent media were evaluated by ELISA (B). In addition, skin morphology after hematoxylin eosin (H&E) staining was assessed qualitatively (C). Blue arrows depict damaged (necrotic) tissue. n = 3; * p < 0.05 for signification different from naïve control tissues. SH-29 and SK-119 were tested at 0.2, 2 and 10% (w/v). C—control; V—vehicle, DMSO at 0.1%; S—SDS at 10%.